Modeling Human Digestive Diseases With CRISPR-Cas9-Modified Organoids.
CRISPR-Cas Systems
/ genetics
Colorectal Neoplasms
/ genetics
Esophageal Neoplasms
/ genetics
Female
Gastrointestinal Diseases
/ genetics
Gastrointestinal Neoplasms
/ genetics
Gastrointestinal Tract
/ pathology
Genetic Predisposition to Disease
Humans
Male
Organoids
Pancreatic Neoplasms
/ genetics
Sensitivity and Specificity
Colorectal Cancer
Gastric Cancer
Inflammatory Bowel Disease
Pancreatic Cancer
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
11
05
2018
revised:
10
11
2018
accepted:
14
11
2018
pubmed:
27
11
2018
medline:
19
3
2019
entrez:
27
11
2018
Statut:
ppublish
Résumé
Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients' tissues are used as models of disease and to test drugs. CRISPR-Cas9 technology can be used to genetically engineer organoids for studies of monogenic diseases and cancer. We review the derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 technology can be used to study these organoids. We discuss burgeoning technologies that are broadening our understanding of diseases of the digestive system.
Identifiants
pubmed: 30476497
pii: S0016-5085(18)35296-X
doi: 10.1053/j.gastro.2018.11.048
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
562-576Informations de copyright
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.